Drug Trial Radar · NCT07141381
A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Aug 27, 2025
Primary completion
Dec 17, 2025
Study completion Apr 16, 2026
Sponsor
- Lead sponsor
- Voronoi, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, randomized, single-center study to evaluate the effect of food and a proton pump inhibitor (PPI) on the pharmacokinetics (PK) of VRN110755 in healthy adult participants. The primary aim of this study is to assess the impact of food and rabeprazole co-administration on the systemic exposure of VRN110755. Safety and tolerability will also be evaluated.
Conditions
- Healthy
Interventions
VRN110755Drug
VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule. It will be given to all participants under fasted, fed, and PPI pre-treated conditions across three periods in a crossover design.
RabeprazoleDrug
Rabeprazole 20 mg will be administered orally once daily for 5 days prior to VRN110755 dosing in Period 3. This is to assess the effect of increased gastric pH (via proton pump inhibition) on the pharmacokinetics of VRN110755.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC₀-inf) of VRN110755Time frame: Up to 312 hours post-dose (for each treatment period)
- Maximum Observed Plasma Concentration (Cmax) of VRN110755Time frame: Up to 312 hours post-dose (for each treatment period)
- Time to Maximum Observed Concentration (Tmax) of VRN110755Time frame: Up to 312 hours post-dose (for each treatment period)
- Comparison of Pharmacokinetic Parameters (AUC and Cmax Ratios) Across Treatment ConditionsTime frame: Up to 312 hours post-dose (for each treatment period)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.